Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
U.S. FDA
Pharma
Sanofi is going all in on Dupixent's next potential nod in COPD
Ahead of an FDA action date this summer, Sanofi is prepping for Dupixent's potential debut in its next "major growth pillar," CEO Paul Hudson said.
Fraiser Kansteiner
Apr 25, 2024 12:37pm
Regulatory tracker: Carvykti scores EC's 2L myeloma nod
Apr 22, 2024 11:35am
Argenx gears up to launch Vyvgart in next potential indication
Apr 16, 2024 2:24pm
FDA review bodes well for MRD-based myeloma approvals
Apr 10, 2024 11:30am
The FDA serves up warning letters to pair of Indian pharmas
Apr 10, 2024 9:58am
FDA weighs another approvable myeloma endpoint. What's at stake?
Apr 9, 2024 9:00am